Inogen Inc
Inogen Inc designs, markets, and sells portable and stationary oxygen concentrators and related respiratory products for people needing long-term oxygen therapy. The company sells through a mix of U.S. business-to-business channels, direct-to-consumer channels, and international distributors, with a growing emphasis on expanding its respiratory product portfolio and overseas reach.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaBattery-powered and portable oxygen therapy devices sold to patients and channel partners.
Home-use oxygen concentrators, including the Voxi 5 introduced through the Yuwell collaboration.
U.S. rental revenue from concentrator deployments to patients on service.
Consumables, replacement components, and related support items for installed devices.
Third-party respiratory products distributed in the U.S. and selected international markets.
Asiakkaat
Inogen sells primarily to home medical equipment providers, distributors, resellers, and other business partners that serve long-term oxygen therapy patients. It also sells direct to consumers in the U.S., where patients buy for cash or insurance-supported use, and it has some exposure to charitable organizations and large house accounts internationally.
HME providers, distributors, and resellers that buy concentrators to serve oxygen therapy patients and shift away from tank delivery models.
Patients purchasing directly in the U.S. through cash or insurance-related channels, often influenced by consumer advertising and prescriber outreach.
Distributors, resellers, gas companies, and home oxygen providers that buy for resale or local patient support across Europe and other markets.
Channel partners and collaborators that broaden product access and help scale distribution into new markets and product lines.
Smaller but relevant buyers that contribute to channel diversity and can support patient access programs.
Strategia
Inogen is focused on expanding its U.S. B2B channel, improving direct-to-consumer productivity, and increasing international adoption through distributors and regional support infrastructure. It is also broadening its product portfolio through the Yuwell collaboration, which adds respiratory products in the U.S. and selected overseas markets while supporting entry into China.
The U.S. market still has low POC penetration, so more HME and reseller adoption can drive volume growth.
Europe offers reimbursement-supported demand and the company already has a meaningful overseas base.
Better lead generation and sales productivity can offset pressure in the consumer channel.
New products can deepen channel relationships and reduce dependence on a narrow oxygen concentrator mix.
Maantiede
Q1/2026The U.S. remains the largest market, but international sales are a major part of the business and represented 39.8% of total revenue in 2025. Europe is the core overseas market, accounting for 85.0% of international sales in 2025, while the company also sells into several other regions and has begun using partners to expand in Asia-Pacific and Latin America.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
The business is exposed to customer concentration, reimbursement complexity, and intense competition in respiratory care. It also depends on third-party manufacturers and distributors, so supply-chain disruption, regulatory issues, or weaker partner demand can quickly affect revenue and margins.
- Customer concentrationVaikutus: KorkeaTodennäköisyys: Korkea
A small number of distributors, HME providers, and partners generate a large share of revenue, so lost volume can materially reduce sales.
Kohdistuu: Top 10 customers were 38.9% of 2025 revenue
- Reimbursement and payer dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
A meaningful portion of demand depends on insurance and Medicare-related reimbursement, which can change utilization and economics.
Kohdistuu: U.S. rentals and insurance-supported patient channels
- Cybersecurity and IT disruptionVaikutus: KeskitasoTodennäköisyys: Korkea
Customer support, sales operations, and internal systems depend on networked IT infrastructure that can be attacked or fail.
Kohdistuu - Competitive pressureVaikutus: KeskitasoTodennäköisyys: Kohtalainen
The company operates in a crowded respiratory device market where rivals can win share through price, features, or channel relationships.
Kohdistuu: Portable oxygen concentrators and related respiratory products
- Supplier and manufacturing dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Reliance on contract manufacturers and limited suppliers can create quality, timing, and cost risks.
Kohdistuu: Foxconn in the Czech Republic and other third-party providers
- Regulatory and compliance riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Medical devices are subject to FDA and international regulatory oversight, and additional clearances or enforcement actions could slow launches or sales.
Kohdistuu
Kirjanpito
Harkinnanvaraiset erätThe company sells products, rentals, service contracts, and freight revenue, so timing and classification can materially affect reported revenue.
Vaikutus: Point-in-time product sales versus rental/service recognition
Acquisitions such as Physio-Assist create assets that must be assessed for impairment and amortization.
Vaikutus: Potential non-cash impairment charges
New rental deployments are a principal use of cash and require capitalization and depreciation over time.
Vaikutus: Affects operating expenses, assets, and cash flow presentation
Sales are made on credit to distributors and HME providers, so collectability estimates matter.
Vaikutus: Accounts receivable valuation and bad debt expense
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Neogen Corporation
NEOG · In Vitro & In Vivo Diagnostic Substances
Neogen Corp develops and sells products and services used to test food, feed, and agricultural inputs for safety and quality, while also providing genomics and animal safety solutions.
Insulet Corporation
PODD · Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells the Omnipod platform, a tubeless continuous insulin delivery system for people with insulin-dependent diabetes.
Longduoduo Co Ltd
LDDD · Services-Health Services
Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct…
INVO Fertility, Inc.
IVF · Surgical & Medical Instruments & Apparatus
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Innovex International, Inc.
INVX · Oil & Gas Field Machinery & Equipment
Päivitetty: 24.9.2026